GlassScriptPhysician profile
Reena Varghese
NPI 1578037750
$19,706.04
in general payments reported to CMS, 2019-2025
30 companies · $3,306 in 2025
The $3,306 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,138 · 2022: $3,267 · 2023: $3,815 · 2024: $5,180 · 2025: $3,306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Consulting Fee: $640 · Travel and Lodging: $26.26 · Education: $14.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,619.98 |
| Consulting Fee | $640.00 |
| Travel and Lodging | $26.26 |
| Education | $14.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,836.16 | 2021-2025 | Enbrel, Otezla, Tavneos |
| Abbvie INC. | $2,232.52 | 2021-2025 | |
| Ucb, INC. | $2,216.80 | 2021-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $2,086.14 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Novartis Pharmaceuticals Corporation | $1,364.39 | 2021-2025 | |
| Pfizer INC. | $1,213.41 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $1,029.72 | 2021-2024 | Tremfya |
| Horizon Therapeutics Plc | $1,010.70 | 2021-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $848.70 | 2021-2025 | Saphnelo |
| Lilly USA, LLC | $780.38 | 2021-2024 | Taltz |
| Glaxosmithkline, LLC. | $707.93 | 2021-2025 | Benlysta, Nucala |
| Aurinia Pharma U.S., INC. | $511.53 | 2021-2024 | Lupkynis |
| Genzyme Corporation | $495.49 | 2021-2025 | |
| Radius Health, INC. | $270.29 | 2021-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $238.96 | 2021-2024 | Cyltezo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $171.71 | 2021-2024 | Orencia |
| Genentech USA, INC. | $145.67 | 2022-2025 | Actemra, Gazyva |
| Sobi, INC | $72.55 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $70.46 | 2021-2025 | Acthar |
| Fresenius Kabi USA, LLC | $67.75 | 2023-2024 | Idacio |
| Sandoz INC. | $53.65 | 2025 | Jubbonti, Hyrimoz |
| Sanofi-Aventis U.S. LLC | $52.99 | 2021 | |
| Kyowa Kirin, INC. | $52.23 | 2023-2025 | |
| Ani Pharmaceuticals, INC. | $43.31 | 2024 | Purified Cortrophin Gel |
| Edwards Lifesciences Corporation | $29.28 | 2021 | |
| Alexion Pharmaceuticals, INC. | $27.82 | 2025 | Strensiq |
| Organon LLC | $23.30 | 2024 | |
| Scilex Pharmaceuticals INC. | $19.19 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $17.55 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $15.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reena Varghese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.